DOCSLIB.ORG

An Oral Gonadotropin-Releasing Hormone Receptor Antagonist For

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
An Oral Gonadotropin-Releasing Hormone Receptor Antagonist For Clinical Pharmacokinetics (2020) 59:297–309 https://doi.org/10.1007/s40262-019-00840-7 REVIEW ARTICLE Clinical Pharmacology of Elagolix: An Oral Gonadotropin‑Releasing Hormone Receptor Antagonist for Endometriosis Mohamad Shebley1 · Akshanth R. Polepally1 · Ahmed Nader1 · Juki W. Ng2 · Insa Winzenborg1 · Cheri E. Klein1 · Peter Noertersheuser1 · Megan A. Gibbs1 · Nael M. Mostafa1 Published online: 21 November 2019 © The Author(s) 2019 Abstract The clinical pharmacology of elagolix was extensively evaluated in clinical studies in healthy subjects and in women with endome- triosis. Elagolix pharmacokinetics (PK) show signifcant population variability, however they are minimally afected by patients’ baseline characteristics and demographics, except for clinically relevant extrinsic and intrinsic factors such as coadministrated strong organic anion transporting polypeptide (OATP) 1B1 inhibitors and severe hepatic impairment, which are contraindications for the use of elagolix. These studies enabled a comprehensive understanding of elagolix mechanism of action and the downstream pharmacodynamic (PD) efects on gonadotropin and ovarian hormones, as well as full characterization of the PK/PD (PKPD) relationships of elagolix at various dosages, including the approved 150 mg once daily and 200 mg twice daily dosing regimens for the management of moderate to severe pain associated with endometriosis. Several model-based analyses have contributed to understanding of the beneft–risk profle of elagolix in patients with endometriosis, through characterization of the exposure relationship with responder rates, with changes in bone mineral density over time, as well as the interaction with coadministered drugs. Collectively, these studies and analyses served as supportive evidence for the efectiveness of the approved dosages and provided general dosing instructions of the frst approved oral gonadotropin-releasing hormone receptor antagonist. Key Points 1 Introduction Elagolix is the frst approved oral gonadotropin-releasing Elagolix (Orilissa™) is a novel, non-peptide oral, short-act- hormone (GnRH) receptor antagonist for moderate to ing competitive gonadotropin-releasing hormone (GnRH) severe pain associated with endometriosis. receptor antagonist approved by the US FDA for the man- agement of moderate to severe pain associated with endome- The clinical pharmacology profle of elagolix was triosis [1], and is currently in development for the manage- fully characterized in several Phase 1 PKPD studies ment of heavy menstrual bleeding associated with uterine along with several model informed drug development fbroids [2, 3]. Both endometriosis and uterine fbroids are approaches. estrogen-dependent conditions [2, 4], and elagolix sup- This comprehensive description of the clinical pharma- presses gonadotropin hormones and ovarian estrogen pro- cology attributes of elagolix provides a reference for duction in a dose-dependent manner, modulating circulating prescribers and clinical pharmacologists who seek to use estrogen levels from partial suppression of estradiol (E2) at or understand the clinical PKPD properties of elagolix. lower doses to nearly full suppression at higher doses [5, 6]. This is in contrast to GnRH receptor agonists, which, after Electronic supplementary material The online version of this an initial stimulatory phase (fare efect), desensitize the article (https ://doi.org/10.1007/s4026 2-019-00840 -7) contains pituitary GnRH receptors and lead to profound suppression supplementary material, which is available to authorized users. of ovarian sex steroid secretion similar to that of ovariecto- * Mohamad Shebley mized women [6]. [email protected] The clinical development program for elagolix included several clinical pharmacology studies, which enabled full 1 Clinical Pharmacology and Pharmacometrics, AbbVie Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA characterization of the pharmacokinetics (PK), pharmaco- dynamics (PD), efects of intrinsic and extrinsic factors, and 2 Pharmaceutical Development, General Medicine, AbbVie Inc., North Chicago, IL, USA population PK/PD, exposure–response (safety and efcacy) Vol.:(0123456789) 298 M. Shebley et al. analyses and physiologically based PK (PBPK) modeling MoA and downstream efects on gonadotropins and ovarian and simulation. A summary of the extensive data, analyses, hormones is shown in Fig. 1. and conclusions generated from these studies is presented herein to ofer a comprehensive overview of the clinical pharmacology attributes of elagolix. 3 Pharmacokinetics (PK) of Elagolix 3.1 Absorption 2 Mechanism of Action of Elagolix Elagolix sodium is a non-peptide, orally bioavailable small Elagolix is a highly potent (KD = 54 pM) GnRH receptor molecule, amorphous solid that is freely soluble in water. antagonist that inhibits endogenous GnRH signaling by At either the 150 or 200 mg dose, elagolix is highly solu- binding competitively to GnRH receptors in the anterior ble per the Biopharmaceutics Classifcation System (BCS) pituitary gland [7]. Elagolix mechanism of action (MoA) is throughout the physiological pH range, it exhibits high diferent from long-acting GnRH receptor agonists, which aqueous solubility (approximately 1 mg/mL), is a zwitte- induce 1–2 weeks of ‘fare-up’ by downregulating GnRH rion with pKa 4.0 (acid) and 7.9 (base), and has an apparent receptors [6]. The competitive nature of elagolix competitive low to moderate permeability (0.5–2.8 × 10−6 cm/s) based on antagonism of the GnRH receptors provides an advantage in vitro Caco-2 studies [7]. These data suggest that elagolix by allowing for rapid and reversible onset and ofset, and could be classifed as a BCS class III drug. Elagolix con- hence more fexibility in modulating the hypothalamic–pitu- tains one chiral center and is manufactured exclusively as itary–gonadal axis. An illustration that describes elagolix the (R)-isomer. The structural formula of elagolix sodium is shown in Fig. 2. Fig. 1 Illustration of GnRH action and function during the normal stream dose-dependent efects on circulating estradiol levels in blood. female menstrual cycle, elagolix mechanism of GnRH receptors’ GnRH gonadotropin-releasing hormone competitive antagonism at the anterior pituitary gland, and its down- Clinical Pharmacology Profle of Elagolix 299 AUC from time zero to infnity (AUC∞ ) of 432.7, 411.8, and 443.9 ng∙h/mL, respectively. However, the geomean AUC ∞ for the colon administration was only 35.22 ng∙h/mL, repre- senting < 10% that of the same dose deposited into the stom- ach/duodenum, jejunum, or ileum, and with a mean Cmax for the colon administration at approximately 38 times lower than that following administration into the ileum (Electronic Supplementary Fig. 1). Several elagolix formulations ranging from suspension to modifed and immediate-release (IR) tablets were evalu- ated throughout the development program and across mul- tiple phase I studies. While variability in the PK profles of elagolix was observed across the tested formulations, the Fig. 2 Structure of elagolix sodium; molecular weight of 653.58. exposures did not vary signifcantly, consistent with a char- Elagolix free acid has a molecular weight of 631.60 acteristic BCS III behavior. An IR tablet formulation was chosen for the endometriosis phase III studies, as well as In clinical PK studies in healthy subjects, elagolix absorp- for the commercial formulation. The fnal commercial tablet tion is rapid, with a time to maximum concentration (Tmax) formulation of elagolix is bioequivalent to the phase III tab- of approximately 1 h. Elagolix exposure (maximum con- let formulation. Representative PK profles of the phase III centration [Cmax] and area under the curve [AUC]) is dose and commercial 200 mg IR tablet formulations is shown in proportional from 100 to 400 mg twice daily [5], and more Fig. 3. Elagolix 150 mg once-daily and 200 mg twice-daily than dose proportional with single doses of 600–1200 mg. A PK parameters at steady state are summarized in Table 1. regional absorption study was conducted in six healthy sub- Dose proportional PK are demonstrated for both elagolix jects to characterize the PK of elagolix 100 mg administered dosages based on the dose normalized Cmax and AUC values; to the stomach via oral solution, and to the jejunum, ileum, elagolix does not accumulate with repeated once daily or and colon via a radiolabeled remote drug delivery capsule twice daily dosing. (InteliSite®). Based on the geometric mean AUC values, elagolix doses delivered as either a solution to the stomach 3.2 Food Efect or in an InteliSite® capsule to the jejunum and ileum resulted in comparable overall systemic exposure, with a geomean The efect of food on elagolix plasma exposure was assessed following administration of a high-fat meal in a pivotal phase Fig. 3 Elagolix plasma con- centration–time profles of the phase III and commercial for- mulations of Orilissa. Symbol represents the mean 300 M. Shebley et al. Table 1 Mean (percentage coefcient of variation) pharmacokinetic scenario for the efect of food on elagolix exposure, and due parameters at steady state of elagolix 150 mg qd or 200 mg bid to the lack of clinical signifcance of the small reduction in Pharmacokinetic parameters 150 mg qd 200 mg bid elagolix exposure with meals, elagolix was administered without regard to meals in the fourth endometriosis phase III T a max (h ) 1.0 (0.5–1.0) 1.0 (0.5–1.5) extension trial. Elagolix clinical efcacy results from all the C max (ng/mL) 574
Load more

Recommended publications
  • [Product Monograph Template
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrORILISSA® elagolix (as elagolix sodium) tablets 150 mg and 200 mg Gonadotropin releasing hormone (GnRH) receptor antagonist Date of Preparation: October 4, 2018 AbbVie Corporation Date of Revision: 8401 Trans-Canada Highway March 3, 2020 St-Laurent, Qc H4S 1Z1 Submission Control No: 233793 ORILISSA Product Monograph Page 1 of 40 Date of Revision: March 3, 2020 and Control No. 233793 RECENT MAJOR LABEL CHANGES Not applicable. TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................................... 4 1. INDICATIONS ................................................................................................................ 4 1.1. Pediatrics (< 18 years of age): .................................................................................. 4 1.2. Geriatrics (> 65 years of age): .................................................................................. 4 2. CONTRAINDICATIONS ................................................................................................. 4 3. DOSAGE AND ADMINISTRATION ................................................................................ 5 3.1. Dosing Considerations ............................................................................................. 5 3.2. Recommended Dose and Dosage Adjustment ......................................................... 5 3.3. Administration .........................................................................................................
    [Show full text]
  • Elagolix) Tablets, for Oral Use
    Important New Update to the Prescribing Information for ORILISSA® (elagolix) tablets, for oral use In February 2021, the ORILISSA Prescribing Information (PI) was updated. The following describes several of the changes in the ORILISSA PI. Please refer to the full PI to review additional changes. The following items have been added to the Prescribing Information (PI): • Section 1 Indications and Usage – Limitations of Use: Limit the duration of use based on the dose and coexisting condition (see Table 1). • Section 4 Contraindications – With known hypersensitivity reaction to ORILISSA or any of its inactive components. Reactions have included anaphylaxis and angioedema [see Adverse Reactions (6.2)]. • Section 6 Adverse Reactions – 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of ORILISSA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Immune system disorders: hypersensitivity reactions (including anaphylaxis, angioedema, and urticaria). The following items have been updated in the PI to read: • Section 4 Contraindications – Taking inhibitors of organic anion transporting polypeptide (OATP) 1B1 (a hepatic uptake transporter) that are known or expected to significantly increase elagolix plasma concentrations [see Drug Interactions (7.2)]. • Section 5 Warnings and Precautions – 5.5 Interactions with Hormonal Contraceptives Advise
    [Show full text]
  • Clinical Study Protocol M12-815 a Phase 3 Study to Evaluate The
    NCT02654054 Elagolix (ABT-620) M12-815 Protocol Amendment 3 1.0 Title Page Clinical Study Protocol M12-815 A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women Incorporating Amendments 1, 2 and 3 AbbVie Investigational Product: Elagolix (ABT-620) Date: 25 September 2017 Development Phase: 3 Study Design: Phase 3, randomized, double-blind, multicenter, placebo-controlled study evaluating the efficacy, safety and tolerability of elagolix alone and in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women 18 to 51 years of age. Investigators: Multicenter Trial: Investigator information is on file at AbbVie Sponsor: AbbVie Sponsor/Emergency Contact: This study will be conducted in compliance with the protocol, Good Clinical Practice and all other applicable regulatory requirements, including the archiving of essential documents. Confidential Information No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie. 1 Elagolix (ABT-620) M12-815 Protocol Amendment 3 1.1 Protocol Amendment: Summary of Changes Previous Protocol Versions Protocol Date Original 06 November 2015 Amendment 1 01 December 2015 Amendment 2 23 June 2016 The purpose of this Amendment is to: ● Update Section 1.1 Protocol Amendment: Summary of Changes from Appendix Q to Appendix
    [Show full text]
  • ORILISSA® (Elagolix) HCP Patient Counseling Guide
    How it works What are possible How do I start Savings & Use & Important What is ORILISSA? & experience side effects? taking ORILISSA? support Safety Information MAKE THE MOVE TO ORILISSA TOGETHER Review this guide with your patients to help them understand their ORILISSA treatment plan and make an informed start together. WHAT IS ORILISSA? ORILISSA® (elagolix) is a prescription medicine used to treat moderate to severe pain associated with endometriosis. It is not known if ORILISSA is safe and effective in children. SAFETY CONSIDERATIONS Do not use ORILISSA if you are pregnant, have osteoporosis or severe liver disease, take medicines called organic anion transporting polypeptide (OATP) 1B1 inhibitors that are known or expected to significantly increase the blood levels of elagolix (the active ingredient in ORILISSA), or have had a serious allergic reaction to ORILISSA or any of the ingredients in ORILISSA. ORILISSA does not prevent pregnancy. It may alter your period, so watch for other signs of pregnancy. Stop taking ORILISSA if you become pregnant. Ask about proper birth control, as some may affect how ORILISSA works. ORILISSA may affect how some birth control works. ORILISSA can cause serious side effects, including bone loss, abnormal liver tests, suicidal thoughts or behaviors, and worsening mood. Talk to your healthcare provider right away if you notice changes such as jaundice, dark amber-colored urine, suicidal thoughts or actions, depression, or worsening mood. 1 Please see Use and additional Important Safety Information on page 7, and full Prescribing Information at rxabbvie.com/pdf/orilissa_pi.pdf. How it works What are possible How do I start Savings & Use & Important What is ORILISSA? & experience side effects? taking ORILISSA? support Safety Information What is ORILISSA? ORILISSA is a pill that’s clinically proven to help relieve endometriosis pain.
    [Show full text]
  • Elagolix for Treating Endometriosis
    Elagolix for Treating Endometriosis Evidence Report June 15, 2018 Prepared for ©Institute for Clinical and Economic Review, 2018 ICER Staff/Consultants University of Colorado Skaggs School of Pharmacy Modeling Group* Steven J. Atlas, MD, MPH R. Brett McQueen, PhD Director, Primary Care Research and Quality Assistant Professor Improvement Network Department of Clinical Pharmacy Massachusetts General Hospital Center for Pharmaceutical Outcomes Research Geri Cramer, BSN, MBA Jonathan D. Campbell, PhD Research Lead, Evidence Synthesis Associate Professor Institute for Clinical and Economic Review Department of Clinical Pharmacy Center for Pharmaceutical Outcomes Research Patricia G. Synnott, MALD, MS Senior Research Lead, Evidence Synthesis Melanie D. Whittington, PhD Institute for Clinical and Economic Review Research Instructor Department of Clinical Pharmacy Varun Kumar, MBBS, MPH, MSc Health Economist Samuel McGuffin Institute for Clinical and Economic Review Professional Research Assistant Department of Clinical Pharmacy Celia Segel, MPP Program Manager Institute for Clinical and Economic Review Daniel A. Ollendorf, PhD Chief Scientific Officer *The role of the University of Colorado Skaggs Institute for Clinical and Economic Review School of Pharmacy Modeling Group is limited to the development of the cost-effectiveness Steven D. Pearson, MD, MSc model, and the resulting ICER reports do not President necessarily represent the views of CU. Institute for Clinical and Economic Review DATE OF PUBLICATION: June 15, 2018 Steven Atlas served as the lead author for the report. Geri Cramer and Patricia Synnott led the systematic review and authorship of the comparative clinical effectiveness section. Varun Kumar was responsible for oversight of the cost-effectiveness analyses and developed the budget impact model.
    [Show full text]
  • DC Healthy Families and DC Healthcare Alliance Prescribing Guide 2020
    MedStar Family Choice - DC Healthy Families and DC Healthcare Alliance Prescribing Guide 2020 (10/01/2020) INTRODUCTION .............................................................................................................................................................................. 5 NONDISCRIMINATION STATEMENT ............................................................................................................................................. 5 PREFACE ....................................................................................................................................................................................... 10 PHARMACY AND THERAPEUTICS (P&T) COMMITTEE ............................................................................................................ 10 PRODUCT SELECTION CRITERIA ............................................................................................................................................... 10 GENERIC AVAILABILITY .............................................................................................................................................................. 10 GENERIC SUBSTITUTION ............................................................................................................................................................ 10 MAIL SERVICE PRESCRIPTIONS ................................................................................................................................................ 11 MEDICAL EXCEPTION .................................................................................................................................................................
    [Show full text]
  • Elagolix, Estradiol, and Norethindrone Acetate (Oriahnn )
    Pharmacy Policy Bulletin Title: Elagolix, estradiol, and norethindrone acetate (Oriahnn®) Policy #: Rx.01.236 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some medications may be subject to precertification, age, quantity, or formulary restrictions (ie limits on non-preferred drugs). Individual member benefits must be verified. This pharmacy policy document describes the status of pharmaceutical information and/or technology at the time the document was developed. Since that time, new information relating to drug efficacy, interactions, contraindications, dosage, administration routes, safety, or FDA approval may have changed. This Pharmacy Policy will be regularly updated as scientific and medical literature becomes available. This information may include new FDA-approved indications, withdrawals, or other FDA alerts. This type of information is relevant not only when considering whether this policy should be updated, but also when applying it to current requests for coverage. Members are advised to use participating pharmacies in order to receive the highest level of benefits. Intent: The intent of this policy is to communicate the medical necessity criteria for Oriahnn (elagolix, estradiol, and norethindrone acetate) as provided under the member's prescription drug benefit. Description: Uterine fibroids, or leiomyomas, and benign neoplasms commonly found in women of reproductive age. Fibroids produce endogenous aromatase, allowing for production
    [Show full text]
  • Using Gnrh Analogues to Reduce Endometriosis Recurrence After Surgery: a Double-Edged Sword
    6 Review Article Page 1 of 6 Using GnRH analogues to reduce endometriosis recurrence after surgery: a double-edged sword Erika P. New, Emad Mikhail Department of Obstetrics and Gynecology, University of South Florida, Morsani College of Medicine, Tampa, FL, USA Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Emad Mikhail, MD. Department of Obstetrics and Gynecology, University of South Florida, Morsani College of Medicine, 2 Tampa General Circle, 6th Floor, Tampa, FL 33606, USA. Email: [email protected]. Abstract: Gonadotropin-releasing hormone (GnRH) analogues, including both agonists and antagonists, are a second line therapy for treating endometriosis. They work by down-regulating the hypothalamic- pituitary-gonadal axis, suppressing ovulation and reducing estrogen levels. GnRH analogues are effective, but they may have significant side effects such as decreased bone mineral density, hot flashes, and mood or sleep disturbances. Due to these side effects, they should only be used for up to 1 year and with add back low dose estrogen and progesterone therapy. GnRH analogues are often used post-operatively to try to reduce endometriosis recurrence after surgery and the optimal duration is for 6 months. Research studies must be interpreted with caution as some do not have a control group for comparison, or the control group are women without treatment. Patients with deep infiltrating endometriosis (DIE) reporting deep dyspareunia may have significant improvement in sexual satisfaction and reduced pain after laparoscopic surgery for endometriosis followed by treatment with a GnRH agonist.
    [Show full text]
  • Article.Pdf (1.330Mb)
    Communications ChemMedChem doi.org/10.1002/cmdc.202000256 1 2 3 Discovery of a Lead Brain-Penetrating Gonadotropin- 4 5 Releasing Hormone Receptor Antagonist with Saturable 6 Binding in Brain 7 8 Roberto B. W. Bekker,[a] Richard Fjellaksel,[b, c, d] Trine Hjornevik,[e] Syed Nuruddin,[f] 9 Waqas Rafique,[a] Jørn H. Hansen,[d] Rune Sundset,[b, c] Ira H. Haraldsen,[g] and 10 [a, f, g] 11 Patrick J. Riss* 12 13 We report the synthesis, radiosynthesis and biological charac- conditions in comparison to pretreatment with a receptor- 14 saturating dose of GnRH antagonist revealed saturable uptake 15 terisation of two gonadotropin-releasing hormone receptor À (0.1%ID/mL) into the brain. 16 (GnRH R) antagonists with nanomolar binding affinity. A small À 17 library of GnRH R antagonists was synthesised in 20–67% 18 overall yield with the aim of identifying a high-affinity Our attention has been drawn towards the gonadotropin 19 antagonist capable of crossing the blood–brain barrier. Binding À releasing hormone receptor (GnRHÀ R) because of its role in 20 affinity to rat GnRH R was determined by autoradiography in 125 hormone related behaviour and in the pathophysiology of 21 competitive-binding studies against [ I]buserelin, and inhib- several diseases. Gonadotropin releasing hormone is a decapep- 22 ition constants were calculated by using the Cheng–Prusoff tide hormone (pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH ) 23 equation. The radioligands were obtained in 46–79% radio- 2 > and a key neurotransmitter in the hypothalamus-pituitary- 24 chemical yield and 95% purity and with a molar activity of gonadal axis.
    [Show full text]
  • Risk Assessment and Risk Mitigation Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 210450Orig1s000 RISK ASSESSMENT and RISK MITIGATION REVIEW(S) Division of Risk Management (DRISK) Office of Medication Error Prevention and Risk Management (OMEPRM) Office of Surveillance and Epidemiology (OSE) Center for Drug Evaluation and Research (CDER) Application Type NDA Application Number 210450 PDUFA Goal Date 07/23/2018 OSE RCM # 2017-1778 Reviewer Name(s) Courtney Cunningham, PharmD Acting Team Leader Laura Zendel, PharmD Deputy Division Director Jamie Wilkins, PharmD Review Completion Date July 23, 2018 Subject Evaluation of Need for a REMS Established Name Elagolix Trade Name Orilissa Name of Applicant AbbVie Inc. Therapeutic Class Nonpeptide, gonadotropin-releasing hormone (GnRH) receptor Formulation(s) antagonist Dosing Regimen 150 mg orally once daily; 200 mg orally twice daily 1 Reference ID: 4295319 Table of Contents EXECUTIVE SUMMARY...................................................................................................................................................3 1 Introduction..............................................................................................................................................................3 2 Background...............................................................................................................................................................3 2.1 Product Information .....................................................................................................................................3
    [Show full text]
  • Appendix B - Product Name Sorted by Applicant
    JUNE 2021 - APPROVED DRUG PRODUCT LIST B - 1 APPENDIX B - PRODUCT NAME SORTED BY APPLICANT ** 3 ** 3D IMAGING DRUG * 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC AMMONIA N 13, AMMONIA N-13 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18 3M * 3M CO PERIDEX, CHLORHEXIDINE GLUCONATE * 3M HEALTH CARE INC AVAGARD, ALCOHOL (OTC) DURAPREP, IODINE POVACRYLEX (OTC) 3M HEALTH CARE * 3M HEALTH CARE INFECTION PREVENTION DIV SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC) ** 6 ** 60 DEGREES PHARMS * 60 DEGREES PHARMACEUTICALS LLC ARAKODA, TAFENOQUINE SUCCINATE ** A ** AAA USA INC * ADVANCED ACCELERATOR APPLICATIONS USA INC LUTATHERA, LUTETIUM DOTATATE LU-177 NETSPOT, GALLIUM DOTATATE GA-68 AAIPHARMA LLC * AAIPHARMA LLC AZASAN, AZATHIOPRINE ABBVIE * ABBVIE INC ANDROGEL, TESTOSTERONE CYCLOSPORINE, CYCLOSPORINE DEPAKOTE ER, DIVALPROEX SODIUM DEPAKOTE, DIVALPROEX SODIUM GENGRAF, CYCLOSPORINE K-TAB, POTASSIUM CHLORIDE KALETRA, LOPINAVIR NIASPAN, NIACIN NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE NIMBEX, CISATRACURIUM BESYLATE NORVIR, RITONAVIR SYNTHROID, LEVOTHYROXINE SODIUM ** TARKA, TRANDOLAPRIL TRICOR, FENOFIBRATE TRILIPIX, CHOLINE FENOFIBRATE ULTANE, SEVOFLURANE ZEMPLAR, PARICALCITOL ABBVIE ENDOCRINE * ABBVIE ENDOCRINE INC LUPANETA PACK, LEUPROLIDE ACETATE ABBVIE ENDOCRINE INC * ABBVIE ENDOCRINE INC LUPRON DEPOT, LEUPROLIDE ACETATE LUPRON DEPOT-PED KIT, LEUPROLIDE ACETATE ABBVIE INC * ABBVIE INC DUOPA, CARBIDOPA MAVYRET, GLECAPREVIR NORVIR, RITONAVIR ORIAHNN (COPACKAGED), ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE
    [Show full text]
  • Clinical Policy: Elagolix (Orilissa)
    Clinical Policy: Elagolix (Orilissa) Reference Number: CP.PHAR.136 Effective Date: 08.28.18 Last Review Date: 11.19 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Elagolix (Orilissa™) is a gonadotropin-releasing hormone (GnRH) receptor antagonist. FDA Approved Indication(s) Orilissa is indicated for the management of moderate to severe pain associated with endometriosis. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Orilissa is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Endometriosis Pain (must meet all): 1. Diagnosis of pain due to endometriosis; 2. Prescribed by or in consultation with a gynecologist; 3. Age ≥ 18 years; 4. Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced (a or b): a. A non-steroidal anti-inflammatory drug (see Appendix B for examples); b. A progestin-containing oral or depot injectable contraceptive agent (see Appendix B for examples); 5. Member does not have osteoporosis; 6. Dose does not exceed 400 mg per day. Approval duration: 6 months for 200 mg twice daily; 12 months for 150 mg once daily B. Other diagnoses/indications 1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid.
    [Show full text]